FDA Approves COPD Medication

Breo Ellipta has been approved for long-term, once-daily maintenance treatment of airflow obstruction in patients.

The U.S. Food and Drug Administration has approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

COPD is a serious lung disease that worsens over time. Symptoms can include chest tightness, chronic cough, and excessive phlegm. Smoking is the leading cause of COPD, according to the National Heart, Lung, and Blood Institute, and COPD is the third-leading cause of death in the United States.

Breo Ellipta decreases inflammation in the lungs and helps muscles around the airways of the lungs stay relaxed to increase airflow. "COPD is a serious disease that makes breathing difficult," said Dr. Curtis Rosebraugh, M.D., MPH, director of Office of Drug Evaluation II in FDA's Center for Drug Evaluation and Research. "The availability of new, long-term maintenance medications provides additional treatment options for the millions of Americans who suffer with COPD."

According to FDA, Breo Ellipta's safety and efficacy were evaluated in 7,700 patients diagnosed with COPD. Its safety and efficacy in patients with asthma have not been established, and it is not approved for the treatment of asthma. It may cause serious side effects, including increased risks of pneumonia and bone fractures. The most common side effects reported by patients using Breo Ellipta include inflammation of the nasal passage, upper respiratory tract infection, headache, and oral candidiasis (thrush). Breo Ellipta was developed by GlaxoSmithKline, Research Triangle Park, N.C., in collaboration with San Francisco-based Theravance.

Download Center

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • Online Safety Training Buyer's Guide

    Use this handy buyer's guide to learn the basics of selecting online safety training and how to use it at your workplace.

  • COVID Return-to-Work Checklist, Fall 2021

    Use this checklist as an aid to help your organization return to work during the COVID-19 pandemic in a safe and healthy manner.

  • SDS Buyer's Guide

    Learn to make informed decisions while searching for SDS Management Software.

  • Risk Matrix Guide

    Risk matrices come in many different shapes and sizes. Understanding the components of a risk matrix will allow you and your organization to manage risk effectively.

  • Industry Safe

Featured Whitepapers

OH&S Digital Edition

  • OHS Magazine Digital Edition - October 2021

    October 2021

    Featuring:

    • TRAINING
      On Route To Safe Material Handling
    • SAFETY CULTURE
      Normalization of Deviations in Performance
    • IH:INDOOR AIR QUALITY
      Arresting Fugitive Dusts
    • PPE:FOOT PROTECTION
      Safety Shoes Make the Outfit for Well-Protected Workers
    View This Issue